Tropical Weight Loss
Tropical Weight Loss
Photo: Polina Tankilevitch
The two molecules do not act in precisely the same way: Wegovy is a GLP-1 analogue whereas tirzepatide is a GIP/GLP-1 agonist. Both are prone to gastrointestinal side-effects.
Athletes often take appetite suppressants to lose weight in order to increase their power to weight ratio. Phentermine is just one of many appetite...
Read More »
The Most Common Indicators That Your Body Is Burning Fat Your urine will be lighter in color. This is because when your body burns fat, it releases...
Read More »The data from the first and largest of Lilly’s pivotal trials of tirzepatide in obesity are in, and the GIP/GLP-1 agonist has smashed the target set by Novo’s Wegovy. Patients given the highest dose in the Surmount-1 study lost more than 20% of their body weight, a result that beat many expectations. Importantly, tolerability also looks competitive to Wegovy and in line with hopes, with Lilly also highlighting low discontinuation rates. Describing the data as “at the top end of what we thought possible”, the company’s chief medical officer Dan Skovronsky said talks will now be sought with regulators about filing on this first trial alone. Previously, Lilly had agreed with the FDA that a filing would be made once the Surmount programme had completed reading out; the three remaining trials are due to yield data in mid-2023. Should the agency agree to review the drug sooner, Lilly’s attempts to grab share of the burgeoning obesity market from Novo would be given a major boost. Mr Skovronsky declined to say whether a recently acquired priority review voucher would be used to speed any submission, but given Lilly's huge investment in this asset, tirzepatide would be presumably be a prime candidate for such a move. “To be clear, we are not announcing an early filing – we are just discussing the next steps” with regulators, Mr Skovronsky told analysts on Lilly’s first-quarter earnings call today. “But given the huge market need, we think it warrants trying to find a path to accelerate [tirzepatide] to market.” The data and the potential for a quicker launch was enough to send Lilly shares up 2% in early trade; Novo Nordisk sank 2.5%. Mike Mason, head of diabetes for Lilly, cautioned that should tirzepatide reach the market “it won’t sprint out of the gate”. While there is considerable long-term potential, demand is likely to build slowly, he said. Poor reimbursement has long been an issue for obesity drugs, although Mr Mason said that is improving, thanks to the significantly better data being generated with tirzepatide and Wegovy versus results seen with older options. “Former agents were more cosmetic than offering real health benefits. The [reimbursement] trends are moving towards better access,” he said, adding that if Lilly can show tirzepatide can help improve related conditions like sleep apnoea, the gates could open even more easily.
As per the USDA guidelines, you should consume two cups of fruits per day, which amounts to two big bananas. Under normal circumstances, two...
Read More »
Puff it up: While people generally have the notion that puffing cheeks can expand the cheek muscles, it is absolutely incorrect. Puffing cheeks...
Read More »The Cost. Plushcare charges a flat-fee of $99 for their appointments. There is no membership requirement or additional charge. In comparison to an urgent care, where an average appointment runs roughly $200 or more, this is an extremely affordable option.
There are thousands of financial products and services out there, and we believe in helping you understand which is best for you, how it works, and will it actually help you achieve your financial goals. We're proud of our content and guidance, and the information we provide is objective, independent, and free. But we do have to make money to pay our team and keep this website running! Our partners compensate us. TheCollegeInvestor.com has an advertising relationship with some or all of the offers included on this page, which may impact how, where, and in what order products and services may appear. The College Investor does not include all companies or offers available in the marketplace. And our partners can never pay us to guarantee favorable reviews (or even pay for a review of their product to begin with). For more information and a complete list of our advertising partners, please check out our full Advertising Disclosure. TheCollegeInvestor.com strives to keep its information accurate and up to date. The information in our reviews could be different from what you find when visiting a financial institution, service provider or a specific product's website. All products and services are presented without warranty.
Generally, experts recommend losing around 1–2 pounds (0.5–0.9 kg) per week, which may involve reducing your calorie intake by around 500–1,000...
Read More »
Is walking too much bad for you? It can be! If your walking routine is too strenuous, you may experience discomfort and it could lead to injuries....
Read More »
What to do when weight loss stalls Forget the crash diets. ... Control your hunger by making the right food choices. ... Track your diet and...
Read More »
Healthy blood supply is vital in plastic surgery procedures and smoking seriously inhibits the circulation of blood to the skin and tissue,...
Read More »
Promotion
Promotion
Promotion
Promotion